Skip to main content

BG Medicine Withdraws IPO

NEW YORK (GenomeWeb News) — BG Medicine said yesterday that it has withdrawn its registration statement with the US Securities and Exchange Commission for an initial public offering.
 
The Waltham, Mass.-based biomarker and molecular diagnostics maker cited “current market conditions” for its decision not to proceed with the IPO. It did not elaborate on those conditions.
 
BG had intended to float its shares on the Euronext Amsterdam Exchange.
 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.